THE USE OF MICE IN TESTS OF IMMUNITY AGAINST YELLOW FEVER
- PMID: 19869938
- PMCID: PMC2132022
- DOI: 10.1084/jem.54.4.533
THE USE OF MICE IN TESTS OF IMMUNITY AGAINST YELLOW FEVER
Abstract
1. A method of testing sera for protective power against yellow fever is described and designated as the intraperitoneal protection test in mice. 2. The test consists essentially of the inoculation of mice intra-peritoneally with yellow fever virus, fixed for mice, together with the serum to be tested, and the simultaneous injection of starch solution into the brain to localize the virus. If the serum lacks protective power the mice die of yellow fever encephalitis. 3. The test is highly sensitive. Consequently it is useful in epidemiological studies to determine whether individuals have ever had yellow fever and in tests to find whether vaccinated persons or animals have in reality been immunized. 4. When mice were given large intraperitoneal injections of yellow fever virus fixed for mice, the virus could be recovered from the blood for 4 days although encephalitis did not occur. If the brain was mildly injured at the time of the intraperitoneal injection, the symptoms of yellow fever encephalitis appeared 6 days later, but the virus was then absent from the blood. 5. Strains of white mice vary greatly in their susceptibility to yellow fever.
Similar articles
-
VACCINATION AGAINST YELLOW FEVER WITH IMMUNE SERUM AND VIRUS FIXED FOR MICE.J Exp Med. 1932 May 31;55(6):945-69. doi: 10.1084/jem.55.6.945. J Exp Med. 1932. PMID: 19870044 Free PMC article.
-
ETIOLOGY OF YELLOW FEVER : X. COMPARATIVE IMMUNOLOGICAL STUDIES ON LEPTOSPIRA ICTEROIDES AND LEPTOSPIRA ICTEROHAEMOORRHAGIAE.J Exp Med. 1920 Jan 31;31(2):135-58. doi: 10.1084/jem.31.2.135. J Exp Med. 1920. PMID: 19868393 Free PMC article.
-
Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates.Vaccine. 1999 Apr 9;17(15-16):1869-82. doi: 10.1016/s0264-410x(98)00487-3. Vaccine. 1999. PMID: 10217584
-
Fractional-dose yellow fever vaccination: how much more can we do with less?Curr Opin Infect Dis. 2019 Oct;32(5):390-393. doi: 10.1097/QCO.0000000000000576. Curr Opin Infect Dis. 2019. PMID: 31335440 Review.
-
[The risk of yellow fever in travellers].Ned Tijdschr Geneeskd. 2006 Aug 19;150(33):1815-20. Ned Tijdschr Geneeskd. 2006. PMID: 16967591 Review. Dutch.
Cited by
-
Neutralization Tests for Quantification of Specific Antibodies Against Yellow Fever Virus.Methods Mol Biol. 2025;2913:79-92. doi: 10.1007/978-1-0716-4458-4_8. Methods Mol Biol. 2025. PMID: 40249427
-
Natural selection for killer receptors and their MHC class I ligands: In pursuit of gene pairs that fit well in tandem.J Leukoc Biol. 2019 Mar;105(3):489-495. doi: 10.1002/JLB.2RI0818-315R. Epub 2018 Nov 30. J Leukoc Biol. 2019. PMID: 30500089 Free PMC article. Review.
-
Neuroinvasive Flavivirus Pathogenesis Is Restricted by Host Genetic Factors in Collaborative Cross Mice, Independently of Oas1b.J Virol. 2023 Jul 27;97(7):e0071523. doi: 10.1128/jvi.00715-23. Epub 2023 Jun 13. J Virol. 2023. PMID: 37310228 Free PMC article.
-
Mapping the risk of yellow Fever infection.Curr Infect Dis Rep. 2012 Jun;14(3):246-55. doi: 10.1007/s11908-012-0256-6. Curr Infect Dis Rep. 2012. PMID: 22477086
-
Lymphoid lesions in poliomyelitis.J Exp Med. 1951 May;93(5):505-12. doi: 10.1084/jem.93.5.505. J Exp Med. 1951. PMID: 14832397 Free PMC article.